Drug Trial Radar · NCT05373264
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 31, 2024
Primary completion
Jul 2030
Study completion Jul 2031
Sponsor
- Lead sponsor
- University Medical Center GroningenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function. Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.
Conditions
- ADPKD
Interventions
Hydrochlorothiazide 25 mgDrug
An oral capsule containing 25mg of hydrochlorothiazide
PlaceboDrug
A matching oral capsule containing placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in kidney function declineTime frame: 156 weeks
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
Uniklinikum Graz
Graz, Austria · Recruiting
Medizinische Universität Innsbruck
Innsbruck, Austria · Recruiting
Universitair Ziekenhuis Antwerpen (UZA)
Antwerp, Belgium · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
University Hospital Leuven
Leuven, Belgium · Recruiting
Hôpital Pellegrin (CHU Bordeaux)
Bordeaux, France · Recruiting
Hospital La Cavale Blanche
Brest, France · Recruiting
Centre Hôpital Universitaire de Lyon
Lyon, France · Recruiting
Hôpitaux de Brabois (CHRU)
Nancy, France · Recruiting
Necker-Enfants Malades Hospital
Paris, France · Recruiting
Charité University Hospital
Berlin, Germany · Recruiting
University Hospital Cologne
Cologne, Germany · Recruiting
Med. Klinik und Poliklinik III, Universitätsklinikum Dresden.
Dresden, Germany · Recruiting
Universitätsklinikum Leipzig
Leipzig, Germany · Recruiting
Amsterdam University Medical Center
Amsterdam, Netherlands · Recruiting
University Medical Center Groningen
Groningen, Netherlands · Recruiting
Erasmus University Medical Center
Rotterdam, Netherlands · Recruiting
Hospital Universitario Mancha Centro
Alcázar de San Juan, Spain · Recruiting
Fundación Puigvert
Barcelona, Spain · Recruiting
Hospital Universitario Vall D'Hebron
Barcelona, Spain · Recruiting
La Fundación Jiménez Díaz
Madrid, Spain · Recruiting
Universitätsspital Bern (Inselsspital)
Bern, Switzerland · Recruiting
Hôpital Fribourgeois (HFR)
Fribourg, Switzerland · Recruiting
Hôpitaux Universitaires de Genève (HUG)
Geneva, Switzerland · Recruiting
Universitätsspital Zürich (USZ)
Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.